Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
暂无分享,去创建一个
Alessandra Bulotta | Vanesa Gregorc | Vincenza Conteduca | Chiara Lazzari | V. Conteduca | G. Improta | Angela Zupa | Giuseppina Improta | Michele Aieta | M. Aieta | Alfredo Tartarone | Rosa Lerose | V. Gregorc | R. Lerose | C. Lazzari | A. Tartarone | A. Bulotta | A. Zupa | Angela Zupa
[1] P. Jänne,et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. , 2010, Cancer research.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] A. Ullrich,et al. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors , 2013, Oncogene.
[4] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[5] R. Moroni,et al. The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines , 2003, Oncogene.
[6] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[7] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[8] William Pao,et al. ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors , 2011, Clinical Cancer Research.
[9] William Pao,et al. Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance , 2012, Science Translational Medicine.
[10] Wei Zheng,et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. , 2011, Cancer research.
[11] J. Yokota,et al. Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Ryohei Katayama,et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.
[15] William Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[16] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[17] Balazs Halmos,et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[19] A. Shaw,et al. Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors , 2012 .
[20] J. Milanowski,et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Sima,et al. Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design , 2011, Clinical Cancer Research.
[22] T. Nakagawa,et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. , 2012, The American journal of pathology.
[23] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[24] Kikuya Kato,et al. Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.
[25] Y. Ishikawa,et al. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer , 2009, Clinical Cancer Research.
[26] Stuart Thomson,et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.
[27] M. Meyerson,et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. , 2005, Cancer research.
[28] P. Jänne,et al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. , 2012 .
[29] Kevin Carroll,et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.
[30] W. Franklin,et al. Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[31] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[32] A. Iafrate,et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Y. Maehara,et al. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny , 2012, Cancer and Metastasis Reviews.
[34] Jeffrey W. Clark,et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. , 2012, The Lancet. Oncology.
[35] W. Pao,et al. ACTIVITY OF AFATINIB/CETUXIMAB IN PATIENTS (PTS) WITH EGFR MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) AND ACQUIRED RESISTANCE (AR) TO EGFR INHIBITORS , 2012 .
[36] Roman K. Thomas,et al. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] A. Shaw,et al. Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) , 2012 .
[38] Susan Quinn,et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] H. Sakamoto,et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). , 2012, Bioorganic & medicinal chemistry.
[40] Huimeng Sun,et al. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. , 2012, Biochemical and biophysical research communications.
[41] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] K. Robison,et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4–ALK levels and induces tumor regression in ALK-driven NSCLC models , 2011, Oncogene.
[43] A. Gemma,et al. F1000 highlights , 2010 .
[44] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[45] T. Mok,et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.
[46] R. Govindan,et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Daniel A. Haber,et al. Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.
[48] N. Altorki,et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.
[49] N. Simon,et al. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[50] Hiroshi Sakamoto,et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.
[51] L. Sequist,et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[53] D. Gandara,et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. , 2006, Clinical lung cancer.
[54] William Pao,et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Patricia L. Harris,et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[56] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[57] L. Fu,et al. Mechanisms of acquired resistance to tyrosine kinase inhibitors , 2011 .
[58] Yi-long Wu,et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). , 2012 .
[59] Y. Yatabe,et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.
[60] H. Uramoto,et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. , 2010, Cancer research.
[61] R. Lai,et al. NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases , 2012, Journal of signal transduction.
[62] M. Ladanyi,et al. New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.
[63] Young Lim Choi,et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.
[64] Hyae-Young Kim,et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] P. Bunn,et al. Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[66] J. Spicer,et al. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992 , 2010, Targeted Oncology.
[67] A. Ardizzoni,et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. , 2011, Lung cancer.
[68] J. Mate,et al. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations , 2011, Clinical Cancer Research.
[69] Denis Maillet,et al. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[70] K. Straif,et al. Advice on formaldehyde and glycol ethers. , 2004, The Lancet. Oncology.
[71] P. Jänne,et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor , 2010, Oncogene.
[72] Chun-Ming Tsai,et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Yan Sun,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. , 2012, The Lancet. Oncology.
[74] F. Hirsch,et al. Finding ALK-positive lung cancer: what are we really looking for? , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[75] M. Meyerson,et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.
[76] Tatiana G. Kutateladze,et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[77] M. Ladanyi,et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay , 2011, Clinical Cancer Research.
[78] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[79] T. Mok,et al. BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) , 2012 .
[80] A. Sandler,et al. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. , 2013, The oncologist.
[81] Junjie Lu,et al. Overcoming erlotinib resistance with tailored treatment regimen in patient‐derived xenografts from naïve Asian NSCLC patients , 2013, International journal of cancer.
[82] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[83] R. Perez-soler,et al. RETRACTION: Erlotinib, an Effective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Induces p27KIP1 Up-Regulation and Nuclear Translocation in Association with Cell Growth Inhibition and G1/S Phase Arrest in Human Non-Small-Cell Lung Cancer Cell Lines , 2007, Molecular Pharmacology.
[84] M. Meyerson,et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models , 2008, Oncogene.
[85] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[87] Y. Bang,et al. Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[88] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[89] Renato Martins,et al. Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.
[90] S. Kimura,et al. A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[91] T. Clackson,et al. Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen , 2011, Chemical biology & drug design.
[92] P. Jänne,et al. Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007) , 2012 .
[93] Jae Cheol Lee,et al. Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.
[94] N. Socci,et al. Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.
[95] T. Clackson,et al. A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies , 2012 .
[96] Ho Yun Lee,et al. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. , 2012, Radiology.
[97] A. Iafrate,et al. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers , 2012, Science Translational Medicine.
[98] William C Hahn,et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. , 2011, Cancer discovery.
[99] H. Hieronymus,et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR , 2011, Nature.
[100] L. Sequist,et al. PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) , 2012 .
[101] Hong Wang,et al. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. , 2008, Cancer research.
[102] S. Kobayashi,et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] Robert Brian Jenkins,et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[104] S. Digumarthy,et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.